Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis

BACKGROUND/OBJECTIVES: Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild‐to‐moderate atopic dermatitis (AD). This pooled post hoc analysis of two phase 3 trials (NCT02118766, NCT02118792) assessed improvement and time to improvement in Investigator&#...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pediatr Dermatol
Päätekijät: Eichenfield, Lawrence F., Yosipovitch, Gil, Stein Gold, Linda F., Kalabis, Mizuho, Zang, Chuanbo, Vlahos, Bonnie, Sanders, Paul, Myers, Daniela E., Bushmakin, Andrew G., Cappelleri, Joseph C., Olivadoti, Melissa, Paller, Amy S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756882/
https://ncbi.nlm.nih.gov/pubmed/32981097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pde.14328
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia